Raymond James cuts BridgeBio Oncology Thera price target to $22
Raymond James maintained a rating of Outperform on BridgeBio Oncology Thera and cut its price target to $22.00 from $24.00,
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.